Author

P. Keskula

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. K. Shalek· 2 shared A. L. Hong· 2 shared B. D. Kynnap· 2 shared C. M. Clinton· 2 shared C. McGuckin· 2 shared D. E. Root· 2 shared E. A. Mullen· 2 shared J. Kaminski· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. K. Shalek

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

B cell directed CAR-T cell therapy results in activation of CD8+ cytotoxic CAR-negative bystander T cells in both non-human primates and patients

J. Kaminski, R. A. Fleming, F. Alvarez-Calderon, C. McGuckin, E. E. Ho, F. Eng, X. Rui, P. Keskula, L. Cagnin, J. Charles, J. Zavistaski, S. P. Margossian, M. A. Kapadia, J. B. Rottman, J. Lane, , U. Gerdemann

The paper identifies a novel mechanism where CAR-T cell therapy activates CD8+ cytotoxic bystander T cells in non-human primates and patients, showing they can kill leukemic cells independently of TCR.

bioRxiv · Sep 28, 2023 · PreprintImmunology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology

Identification and tracking of alloreactive T cell clones in Rhesus Macaques through the RM-scTCR-Seq platform.

U. Gerdemann, R. A. Fleming, J. Kaminski, C. McGuckin, X. Rui, J. F. Lane, P. Keskula, L. Cagnin, A. K. Shalek, V. Tkachev, L. S. Kean

The paper introduces RM-scTCR-Seq, a method for tracking T cell clones in Rhesus Macaques, and applies it to study GVHD.

bioRxiv · Oct 29, 2021Immunology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology